argenx (NASDAQ:ARGX) Downgraded by ValuEngine to “Hold”

ValuEngine downgraded shares of argenx (NASDAQ:ARGX) from a buy rating to a hold rating in a research note issued to investors on Thursday, ValuEngine reports.

Other research analysts also recently issued research reports about the company. Piper Jaffray Companies upped their price objective on argenx from $161.00 to $182.00 and gave the stock an overweight rating in a report on Thursday, May 23rd. Robert W. Baird began coverage on argenx in a report on Thursday, June 27th. They set an outperform rating and a $170.00 price objective on the stock. Zacks Investment Research downgraded argenx from a buy rating to a hold rating in a report on Tuesday, July 16th. Finally, Stifel Nicolaus reaffirmed a buy rating and set a $154.00 price objective on shares of argenx in a report on Thursday. Two analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. The company currently has a consensus rating of Buy and an average price target of $152.27.

NASDAQ:ARGX traded down $1.97 during trading hours on Thursday, hitting $142.61. 125,354 shares of the stock were exchanged, compared to its average volume of 113,067. The company’s 50 day moving average is $140.44. argenx has a twelve month low of $63.81 and a twelve month high of $150.92. The firm has a market capitalization of $4.52 billion, a P/E ratio of -60.69 and a beta of 1.18.

Large investors have recently bought and sold shares of the business. Marshall Wace LLP acquired a new position in argenx during the 1st quarter worth $121,000. SG Americas Securities LLC bought a new stake in shares of argenx during the 1st quarter valued at $134,000. First Trust Advisors LP bought a new stake in shares of argenx during the 2nd quarter valued at $212,000. Virtu Financial LLC bought a new stake in shares of argenx during the 1st quarter valued at $217,000. Finally, NumerixS Investment Technologies Inc bought a new stake in shares of argenx during the 1st quarter valued at $250,000. 68.02% of the stock is currently owned by hedge funds and other institutional investors.

About argenx

argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company's lead product candidates include ARGX-113 that completed Phase 2 clinical trials for the treatment of autoimmune diseases, including myasthenia gravis, immune thrombocytopenia, and pemphigus vulgaris; and ARGX-110, which is in Phase 1/2 clinical trials for the treatment of T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome.

Featured Article: What does a dividend yield signify to investors?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for argenx (NASDAQ:ARGX)

Receive News & Ratings for argenx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for argenx and related companies with MarketBeat.com's FREE daily email newsletter.